Analysis of Calprotectin as an Early Marker of Infections Is Economically Advantageous in Intensive Care-Treated Patients
Open Access
- 1 August 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (8) , 2156
Abstract
Calprotectin is released from neutrophil granulocytes upon activation. Several studies have indicated that plasma calprotectin is an early determinant of bacterial infections, which may serve as a diagnostic tool facilitating decision making on antibiotic treatment. The study objective was to explore the health and economic implications of calprotectin as a predictive tool to initiate antimicrobial therapy in a cohort of critically ill patients. Thus, data obtained from a previously published study on calprotectin as a hypothetical early biomarker of bacterial infections in critically ill patients were evaluated regarding the potential cost-effective impact of early analysis of calprotectin on an earlier start of antibiotic treatment. Under the assumption that calprotectin is used predictively and comparators (white blood cells, procalcitonin, and C-reactive protein) are used diagnostically, a cost-effective impact of EUR 11,000–12,000 per patient would be obtained. If calprotectin would be used predictively and comparators would be used predictively for 50% of patients, it is hypothesized that cost-effectiveness would be between EUR 6000 and 7000 per patient, based on reduced stay in the ICU and general ward, respectively. Furthermore, predictive use of calprotectin seems to reduce both mortality and the length of hospital stay. This health economic analysis on the predictive use of plasma calprotectin, which facilitates clinical decision making in cases of suspected sepsis, indicates that such determination has a cost-saving and life-saving impact on the healthcare system.Keywords
Funding Information
- Uppsala University Hospital Research Fund
This publication has 26 references indexed in Scilit:
- Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level*Critical Care Medicine, 2018
- Hospital-related cost of sepsis: A systematic reviewJournal of Infection, 2017
- Performance of Plasma Calprotectin as a Biomarker of Early Sepsis: A Pilot StudyBiomarkers in Medicine, 2016
- Neutrophil Migration Under Normal and Sepsis ConditionsCardiovascular & Hematological Disorders-Drug Targets, 2015
- Early management of sepsisClinical and Experimental Emergency Medicine, 2014
- IL-6 in Inflammation, Immunity, and DiseaseCold Spring Harbor Perspectives in Biology, 2014
- Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First HourCritical Care Medicine, 2014
- Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*Critical Care Medicine, 2006
- The Duration of Hypotension before the Initiation of Antibiotic Treatment Is a Critical Determinant of Survival in a Murine Model ofEscherichia coliSeptic Shock: Association with Serum Lactate and Inflammatory Cytokine LevelsThe Journal of Infectious Diseases, 2006
- Calprotectin – a pleiotropic molecule in acute and chronic inflammation.Physiological Research, 2004